Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts
- 31 December 1995
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (13-14) , 2335-2340
- https://doi.org/10.1016/0959-8049(95)00419-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- New targets for pyrimidine antimetabolites for the treatment of solid tumoursPharmacy World & Science, 1994
- Head and Neck CancerNew England Journal of Medicine, 1993
- Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)Cancer Treatment Reviews, 1993
- Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude miceHead & Neck, 1989
- Variability in DNA-adduct levels after in vivo treatment with the antitumor drug cisplatinJournal of Inorganic Biochemistry, 1989
- Synergistic effects of cis-platinum and cystosine arabinoside on ovarian carcinoma cell lines, demonstrated by dual-parameter flow cytometryGynecologic Oncology, 1989
- 2',2'-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia CellsNucleosides, Nucleotides and Nucleic Acids, 1989
- Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosidesThe Journal of Organic Chemistry, 1988
- Effects of CIS-diamminedichloroplatinum on DNA incorporation and cytotoxicity of 1-β-d-arabinofuranosylcytosineBiochemical Pharmacology, 1986
- Ototoxicity of cis-diamminedichloroplatinum (II): Influence of dose, schedule and mode of administrationEuropean Journal of Cancer and Clinical Oncology, 1983